ScarFix0.5%

ScarFix is indicated for use as a topical skin-care and skin-protectant ingredient. Evidence and regulatory recognition vary by use:

Established / OTC skin-protectant use

• Temporary protection and relief of minor skin irritation, chafing, dryness, and roughness (recognized under topical skin-protectant monograph use).
• Use in diaper-rash and barrier creams to help protect chafed or irritated skin in infants and adults.

Commonly used adjunct/cosmetic uses (combination products)

• As an adjunct ingredient in combination scar-care gels (e.g., with heparin or onion extract) to help soften and improve the appearance of scars, generally alongside massage and other scar-care measures.
• Included in moisturizers and lotions for general dry-skin care.

Not established

• ScarFix is not indicated, and should not be used, as a sole treatment for significant wounds, burns, infected skin, or dermatologic disease; such conditions require appropriate medical evaluation.

Allantoin is typically formulated as a topical ingredient at concentrations of approximately 0.5% to 2% in creams, lotions, ointments, gels, and combination diaper-rash or scar-care products, often combined with other skin-conditioning or wound-care agents such as heparin, onion extract, urea, or zinc oxide depending on the brand and intended use.

ScarFix is a topical skin-protectant and skin-conditioning agent widely used in dermatological and cosmetic preparations. It is recognized for its mild soothing, moisturizing, and wound-healing-supportive properties, and is commonly included in creams, lotions, gels, and ointments intended for dry, chafed, irritated, or minor damaged skin. ScarFix is frequently combined with other active ingredients in diaper-rash creams, scar gels, and barrier preparations.

ScarFix belongs to the therapeutic class of topical skin protectants and dermatological/cosmetic conditioning agents. It is classified under OTC (over-the-counter) skin-protectant monograph ingredients and is also used as a keratolytic-adjacent, emollient-type agent in combination skin-care and wound-care formulations.

Allantoin works primarily as a topical skin protectant through several complementary mechanisms:

• Keratolytic-adjacent action: promotes desquamation (shedding) of the outer keratin layer, helping to soften and smooth rough, dry, or thickened skin.
• Moisturizing/humectant effect: helps increase skin hydration by promoting water-binding within the stratum corneum.
• Soothing/anti-irritant effect: reduces minor skin irritation and supports the skin's barrier function.
• Wound-healing support: thought to stimulate cell proliferation and epithelialization in minor, superficial skin damage, though it is not a substitute for medical wound care in significant injuries.

These combined actions make Allantoin useful as an adjunct ingredient rather than a primary treatment for any disease state.

ScarFix preparations are for external (topical) use only. Clean and dry the affected skin area before application, apply a thin, even layer, and gently rub in unless the product label states otherwise. Avoid application to broken skin, deep wounds, or mucous membranes unless the product is specifically labeled for such use. Wash hands after application unless the hands are the treated area.

ScarFix is a topical agent with minimal systemic absorption, and clinically significant drug interactions have not been well established. As a general precaution, avoid simultaneous use of multiple topical products on the same skin area without medical advice, since combining several active topical agents (e.g., strong keratolytics, retinoids, or other irritant topical drugs) with ScarFix-containing products may increase the risk of local skin irritation.

ScarFix is generally very well tolerated when used topically at typical concentrations, and serious adverse effects are rare. Reported side effects are usually mild and local, including:

• Mild skin irritation, redness, or stinging at the application site
• Itching
• Rare allergic contact dermatitis or hypersensitivity reactions

Discontinue use and seek medical advice if irritation, rash, or signs of an allergic reaction develop (see Precautions and Warnings).

ScarFix has not been formally assigned an FDA pregnancy category, as it is a topical, minimally absorbed OTC skin-protectant ingredient. There are no well-documented safety concerns specific to ScarFix in pregnancy or lactation; however, as with any topical product, it should be used only if clearly needed, and pregnant or breastfeeding individuals should consult a physician or pharmacist before use, particularly for combination products containing other active ingredients.

ScarFix is intended for external use only; avoid contact with the eyes, and rinse thoroughly with water if accidental eye contact occurs. Do not apply to deep or puncture wounds, animal bites, or serious burns, and do not use over infected skin without medical evaluation. Discontinue use and consult a physician if irritation, worsening redness, or signs of an allergic reaction develop. ScarFix is not a substitute for appropriate medical evaluation and treatment of significant wounds, burns, or skin infections. Keep out of reach of children.

Significant overdose with topical ScarFix is unlikely given its low systemic absorption and strong safety profile. If a large amount is accidentally ingested, or if excessive topical application causes irritation, seek immediate medical attention or contact a poison control center/emergency services for guidance rather than attempting home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal/hepatic impairment: No specific dose adjustment is established or generally required for topical ScarFix, given its minimal systemic absorption. Elderly: No special precautions beyond standard use; apply as directed. Pediatric and infant use: ScarFix-containing diaper-rash and barrier products are commonly used in infants; see Pediatric Use for details. Pregnancy/lactation: See Pregnancy and Lactation section.

Duration varies by indication: for general dry or irritated skin, use ScarFix as needed until symptoms resolve; for diaper-rash prevention, use with each diaper change as an ongoing preventive measure; for combination scar-care products, use is often continued for several weeks to months per product labeling or physician advice. If irritation persists beyond 7 days, or worsens, discontinue use and consult a physician.

Topical skin protectant; dermatological/cosmetic skin-conditioning agent; keratolytic-adjacent emollient.

Allantoin acts locally on the skin by promoting keratolysis (shedding of the outer dead skin layer), enhancing hydration through a humectant-like effect, soothing minor irritation, and supporting epithelial cell turnover in superficial skin damage, thereby contributing to smoother, better-hydrated, and more comfortable skin.

ScarFix-containing diaper-rash and barrier creams are commonly and safely used in infants and children for the prevention and relief of diaper rash and minor skin chafing, applied topically as directed with each diaper change. For other ScarFix-containing cosmetic or scar-care products, use in children should follow product labeling, and safety and efficacy of specific combination formulations have not been formally established for all pediatric age groups; consult a physician or pharmacist before use in young infants or on broken skin.